SCHEMBL25399746

SCHEMBL25399746

FC(F)(F)c1cc(SCc2nc3cc(Br)ccc3[nH]2)ccn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.40
▸ RAB9A P51151 6/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ PKM P14618 2/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ LMNA P02545 3/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ PDE10A Q9Y233 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ TYMS P04818 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30040677 1.00 NPC1 (0.40) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL30579945 0.86 NPC1 (0.40) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL30579946 0.86 NPC1 (0.40) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL21611980 0.86 NPC1 (0.48) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL26260600 0.85 RAB9A (0.43) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL21611996 0.84 PDE10A (0.40) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL21611999 0.84 NPC1 (0.38) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL21614710 0.83 GAA (0.44) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL21614778 0.83 SMN1; SMN2 (0.48) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL25434245 0.81 ABCB1 (0.39) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4085054-B1 NEW PQSR INVERSE AGONISTS HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) 2025-02-19 — — EP disclosed
US-20230286942-A1 NEW PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2023-09-14 — — US disclosed
US-20230286942-A1 NEW PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2023-09-14 — — US disclosed
US-20230286942-A1 NEW PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2023-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286942-A1 NEW PqsR INVERSE AGONISTS QRFPR, P2RY11, GPR55 NPC1 4374/4885RAB9A 991/4885SMN1; SMN2 4177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback